Drawing for AGC

USPTO serial 97132594

AGC

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
WOLD, BARBARA NIELSEN
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with AGC?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeffrey H. Kaufman

Jeffrey H. Kaufman MUNCY, GEISSLER, OLDS & LOWE, P.C.125 S. Royal StreetAlexandria, VA 22314UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemical preparations for use in the manufacture of pharmaceuticals for ophthalmological preparations and pharmaceutical products for ophthalmological use; Monoclonal antibodies for scientific purposes, other than for medical or veterinary use; Stem cells, other than for medical or veterinary purposes; Cell culture media for scientific or research purposes; Active chemical ingredients for use in the manufacture of pharmaceuticals for ophthalmological preparations and pharmaceutical products for ophthalmological use; Nucleic acids for scientific purposes, namely, nucleic acid for laboratory use; Viral vectors other than for medical and veterinary use, namely, viral vectors for laboratory useACTIVE—
005Pharmaceutical preparations, namely, ophthalmological preparations and pharmaceutical products for ophthalmological use; Germicides and fungicides; Insecticides; Weedkillers; Cultures of microorganisms for medical or veterinary use; Chemical reagents for medical or veterinary purposes; Nucleic acid sequences for medical and veterinary purposes; Viral vectors for medical useACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Oct 2, 2023MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 2, 2023ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 16, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 16, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 16, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 28, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 3, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 3, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 14, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 29, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 29, 2022XAECEXAMINER'S AMENDMENT ENTERED—
Nov 29, 2022GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 29, 2022GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 29, 2022CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 8, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 7, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 7, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 6, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 6, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 6, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 27, 2022DOCKASSIGNED TO EXAMINER—
Nov 23, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 22, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance